Vitru

Vitru ROE

Delisted

The Return on Equity (ROE) of Vitru (VTRU) as of Oct 21, 2026 is 4.76 %. In the previous year, Return on Equity (ROE) was 4.29 % — a change of 10.97% (higher).

ROE

4.76 %

YoY

10.97%

Last updated:

In 2023, Vitru's return on equity (ROE) was 4.76 %, a 10.97% increase from the 4.29 % ROE in the previous year.

The Vitru ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-8.70 BRL
Jan 1, 2019
-14.67 BRL
Jan 1, 2020
5.33 BRL
Jan 1, 2021
6.62 BRL
Jan 1, 2022
4.29 BRL
Jan 1, 2023
4.76 BRL
The Vitru ROE history
YEARROEYoY
4.76 %+10.97%
4.29 %-35.21%
6.62 %+24.30%
5.33 %-136.32%
-14.67 %+68.56%
-8.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vitru Stock analysis

What does Vitru do? Vitru Ltd is a British company specializing in the production and sale of high-quality and innovative implants and medical devices. The company was founded in 2011 and is based in London. Its initial focus was on developing products for human body reconstruction, including implants for knees, hips, and shoulders, as well as products for tendon and ligament repair. Vitru produces high-quality products that meet the highest standards by using state-of-the-art technologies and materials. The company has quickly become a leading provider in this market and continues to expand its offerings and expertise. This includes not only the manufacturing of implants but also the development and production of instruments and procedures that enable more precise and efficient surgeries for doctors and surgeons. Vitru also offers products and services in the areas of phenotyping and genotyping, collecting data on a person's genetic characteristics and using that information for personalized medicine and diagnostics. Another business field of Vitru is 3D printing. By utilizing 3D printing technology, the company can rapidly manufacture products and better meet customer needs. Vitru offers a wide range of implants that can be customized to individual customer requirements. In this context, Vitru has also engaged in the production of masks and other facial protection products to contribute to the fight against the COVID-19 pandemic. Vitru's products are known for their high quality, durability, and functionality. They are distributed both in the UK and worldwide and are used in orthopedics, neurosurgery, and other medical specialties. The company has a clear mission to be a global leader in the development and manufacturing of medical devices and implants tailored to the needs of patients and surgeons. To fulfill this mission, Vitru collaborates closely with professionals in the fields of medicine and technology. The company also works closely with hospitals and research institutions to stay up to date with the latest developments in medicine and technology and incorporate them into its products. An example of this is the development of knee implants specifically designed for women to better accommodate their needs. Overall, Vitru has established itself as an important player in the medical technology industry and is committed to improving healthcare for patients worldwide. Vitru is one of the most popular companies on Eulerpool.

ROE Details

Decoding Vitru's Return on Equity (ROE)

Vitru's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Vitru's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Vitru's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Vitru’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Vitru stock

Return on Equity (ROE) of Vitru is 4.76 % in 2023.

Return on Equity (ROE) of Vitru changed from 4.29 % to 4.76 %, representing a 10.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Vitru since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Vitru with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Vitru

All Key Metrics — Vitru